Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Fig. 5

MMP9 is mainly expressed by tumor-infiltrating CD16 + neutrophils. A Frequency of immune subsets into the CD45+ cells. B T-SNE representation of immune subset in an illustrative case. C MMP9 expression: delta (d) Mean Fluorescence Intensity (MFI) [MFI mmp9—MFI fluorescence minus one (fmo)] in each immune subset. D MMP9 mean fluorescence intensity (MFI) shift between stained and unstained neutrophils (left) and inflammatory dendritic cells (right). E Percent of positive neutrophils (present in all cases) and inflammatory dendritic cells (present in only 3/5 cases) for MMP9. F T-SNE representation of the markers including MMP9 in an illustrative case. G Normalized expression of MMP9 based on CD45+ cell frequency and dMFI [%CD45*dFMI]

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us